核心增长较快的卒中患者从血管内治疗获益更大
这项回顾性队列研究纳入806例发病4.5小时内的大血管闭塞急性缺血性卒中患者,比较血管内取栓(EVT)与仅静脉溶栓(IVT)的疗效。结果显示EVT的获益受核心增长速率介导:核心增长>25 mL/h的患者EVT获益显著,而<15 mL/h者两组无显著差异。
要点
- EVT与核心增长速率对良好预后和最终梗死体积存在显著交互作用。
- 核心增长>25 mL/h者EVT较仅IVT显著提高良好预后并缩小梗死体积。
- 核心增长<15 mL/h者EVT与仅IVT在预后和梗死体积上无显著差异。
核心结论
- 在发病4.5小时内,核心增长较快的患者从EVT相比IVT的获益更大。
研究设计与样本
- 回顾性队列研究纳入806例大血管闭塞急性缺血性卒中患者,429例接受EVT(再通率61.6%),377例仅接受IVT(再通率44.7%)。
- 核心增长速率由灌注CT上的急性核心体积除以发病至灌注CT时间估算。
主要发现
- EVT与核心增长速率对良好临床结局存在显著交互作用(交互OR=1.03 [1.01-1.05],P=0.007)。
- EVT与核心增长速率对最终梗死体积存在显著交互作用(交互OR=-0.44 [-0.87至-0.01],P=0.047)。
- 核心增长>25 mL/h者,EVT较仅IVT提高良好结局几率(校正OR=3.62 [1.21-10.76],P=0.021),最终梗死体积更小(37.5 vs 73.9 mL,P=0.012)。
- 核心增长<15 mL/h者,EVT与仅IVT在良好结局(校正OR=1.44 [0.97-2.14],P=0.070)和最终梗死体积(22.6 vs 21.9 mL,P=0.551)上无显著差异。
关键数值与推荐
- 良好临床结局定义为3个月改良Rankin量表评分0-2分。
- 组织学结局为最终梗死体积。
临床怎么用
- 对于发病4.5小时内的大血管闭塞患者,核心增长速率可辅助筛选更可能从EVT获益的人群。
- 核心增长>25 mL/h的患者应积极考虑EVT,而核心增长<15 mL/h者需个体化评估EVT的必要性。
局限性
- 本研究为回顾性队列研究,仅纳入发病4.5小时内且接受再灌注治疗的患者。
- 仅IVT组为无法获得EVT的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: This study aimed to explore whether the therapeutic benefit of endovascular thrombectomy (EVT) was mediated by core growth rate. METHODS: This retrospective cohort study identified acute ischemic stroke patients with large vessel occlusion and receiving reperfusion treatment, either EVT or intravenous thrombolysis (IVT), within 4.5 hours of stroke onset. Patients were divided into 2 groups: EVT versus IVT only patients (who had no access to EVT). Core growth rate was estimated by the acute core volume on perfusion computed tomography divided by the time from stroke onset to perfusion computed tomography. The primary clinical outcome was good outcome defined by 3-month modified Rankin Scale score of 0-2. Tissue outcome was the final infarction volume. RESULTS: A total of 806 patients were included, 429 in the EVT group (recanalization rate of 61.6%) and 377 in the IVT only group (recanalization rate of 44.7%). The treatment effect of EVT versus IVT only was mediated by core growth rate, showing a significant interaction between EVT treatment and core growth rate in predicting good clinical outcome (interaction odds ratio=1.03 [1.01-1.05], P=0.007) and final infarct volume (interaction odds ratio=-0.44 [-0.87 to -0.01], P=0.047). For patients with fast core growth of >25 mL/h, EVT treatment (compared with IVT only) increased the odds of good clinical outcome (adjusted odds ratio=3.62 [1.21-10.76], P=0.021) and resulted in smaller final infarction volume (37.5 versus 73.9 mL, P=0.012). For patients with slow core growth of <15 mL/h, there were no significant differences between the EVT and the IVT only group in either good clinical outcome (adjusted odds ratio=1.44 [0.97-2.14], P=0.070) or final infarction volume (22.6 versus 21.9 mL, P=0.551). CONCLUSIONS: Fast core growth was associated with greater benefit from EVT compared with IVT in the early <4.5-hour time window.
引用
- Lin L, Zhang H, Chen C, et al. Stroke Patients With Faster Core Growth Have Greater Benefit From Endovascular Therapy. Stroke. 2021. PMID: 34583531. doi:10.1161/STROKEAHA.121.034205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。